Twist Bioscience Corporation filed a Form 8-K on November 12, 2026, announcing the release of its financial results for the quarter and fiscal year ended September 30, 2026.
Key Highlights
- Filing date: November 12, 2026, the same date as the earliest event reported.
- Reporting period: Quarter and fiscal year ended September 30, 2026.
- Press release: Twist Bioscience issued a press release titled "Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial Results," furnished as Exhibit 99.1.
- Disclosure item: The filing was made under Item 2.02, Results of Operations and Financial Condition.
- Signing officer: Dennis Cho, Chief Legal Officer and Corporate Secretary, signed the filing on behalf of the registrant.
Twist Bioscience Discloses Fiscal 2026 Annual and Q4 Earnings Filing
Twist Bioscience Corporation (NASDAQ:TWST), headquartered in South San Francisco, California, filed a current report on November 12, 2026, disclosing that it had issued a press release announcing its financial results for the fiscal fourth quarter and full fiscal year ended September 30, 2026. The filing was submitted under Item 2.02 of Form 8-K, which covers Results of Operations and Financial Condition, according to the filing.
The company disclosed that the full text of the press release is furnished as Exhibit 99.1 to the current report. The filing noted that the information provided under Item 2.02, including Exhibit 99.1, "is being furnished and shall not be deemed to be 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended," meaning it is not subject to the liabilities of that section and is not automatically incorporated by reference into other filings unless expressly specified.
The filing was signed by Dennis Cho, Chief Legal Officer and Corporate Secretary of Twist Bioscience Corporation, on November 12, 2026. The company's common stock is listed on The Nasdaq Global Select Market under the trading symbol TWST, as stated on the cover page of the filing. No financial figures from the press release itself were reproduced within the body of the 8-K filing.
What Was Disclosed
Twist Bioscience filed a Form 8-K on November 12, 2026, notifying the public that it issued a press release covering fiscal Q4 and full year 2026 results. The press release was furnished as Exhibit 99.1 and is not deemed "filed" under the Exchange Act.




Please wait processing your request...